34.25
price up icon2.64%   0.88
after-market Dopo l'orario di chiusura: 34.25
loading
Precedente Chiudi:
$33.37
Aprire:
$33.09
Volume 24 ore:
2.97M
Relative Volume:
1.00
Capitalizzazione di mercato:
$6.50B
Reddito:
$217.77M
Utile/perdita netta:
$-438.86M
Rapporto P/E:
-14.21
EPS:
-2.41
Flusso di cassa netto:
$-456.33M
1 W Prestazione:
+2.73%
1M Prestazione:
-5.96%
6M Prestazione:
+26.43%
1 anno Prestazione:
+18.72%
Intervallo 1D:
Value
$32.37
$34.73
Intervallo di 1 settimana:
Value
$31.77
$34.73
Portata 52W:
Value
$21.62
$39.54

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name
Nome
Bridgebio Pharma Inc
Name
Telefono
(650) 391-9740
Name
Indirizzo
3160 PORTER DR., PALO ALTO, CA
Name
Dipendente
730
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
BBIO's Discussions on Twitter

Confronta BBIO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BBIO
Bridgebio Pharma Inc
34.25 6.33B 217.77M -438.86M -456.33M -2.41
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-31 Iniziato Redburn Atlantic Buy
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-10-03 Iniziato Oppenheimer Perform
2024-09-04 Iniziato Piper Sandler Overweight
2024-03-21 Ripresa Raymond James Outperform
2024-01-31 Iniziato BMO Capital Markets Market Perform
2023-12-08 Iniziato Wells Fargo Overweight
2023-11-07 Iniziato Citigroup Buy
2023-10-24 Iniziato Cantor Fitzgerald Overweight
2023-07-18 Downgrade Jefferies Buy → Hold
2023-04-19 Iniziato Evercore ISI Outperform
2023-02-06 Iniziato Cowen Outperform
2021-12-27 Reiterato Mizuho Buy
2021-12-27 Reiterato SVB Leerink Outperform
2021-09-10 Aggiornamento BofA Securities Neutral → Buy
2021-05-21 Iniziato UBS Buy
2021-03-22 Reiterato Goldman Buy
2021-02-22 Ripresa JP Morgan Overweight
2021-02-09 Ripresa Goldman Buy
2021-01-11 Reiterato H.C. Wainwright Buy
2020-12-10 Reiterato H.C. Wainwright Buy
2020-06-25 Iniziato BofA/Merrill Neutral
2020-05-19 Iniziato BTIG Research Buy
2020-04-13 Iniziato H.C. Wainwright Buy
2020-02-19 Iniziato Mizuho Buy
2019-07-26 Iniziato Raymond James Outperform
2019-07-22 Iniziato BMO Capital Markets Outperform
2019-07-22 Iniziato Goldman Buy
2019-07-22 Iniziato JP Morgan Overweight
2019-07-22 Iniziato Jefferies Buy
2019-07-22 Iniziato Piper Jaffray Overweight
2019-07-22 Iniziato SVB Leerink Outperform
Mostra tutto

Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie

pulisher
May 28, 2025

Nuveen Asset Management LLC Cuts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

May 28, 2025
pulisher
May 27, 2025

Possible Bearish Signals With BridgeBio Pharma Insiders Disposing Stock - simplywall.st

May 27, 2025
pulisher
May 26, 2025

BridgeBio Pharma’s SWOT analysis: stock soars on Attruby success, pipeline potential - Investing.com Nigeria

May 26, 2025
pulisher
May 26, 2025

Propionic Acidemia Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Bridge Bio Pharma, HemoShear Therapeutics, Moderna Therapeutics - Barchart.com

May 26, 2025
pulisher
May 24, 2025

Cetera Investment Advisers Takes $1.02 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

May 24, 2025
pulisher
May 21, 2025

The Play On BridgeBio Pharma: Great Expectations For Attruby (NASDAQ:BBIO) - Seeking Alpha

May 21, 2025
pulisher
May 21, 2025

BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment - Insider Monkey

May 21, 2025
pulisher
May 21, 2025

Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com

May 21, 2025
pulisher
May 20, 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

BridgeBio (BBIO) Shares Positive Phase 3 Study Data | BBIO Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM | BBIO Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Breakthrough: New ATTR-CM Treatment Cuts Heart Complications by 43%, Shows Fastest Clinical Benefits Ever - Stock Titan

May 20, 2025
pulisher
May 19, 2025

BridgeBio’s acoramidis shows promise in ATTR-CM study By Investing.com - Investing.com Nigeria

May 19, 2025
pulisher
May 19, 2025

BridgeBio Pharma Reports Phase 3 Data Linking TTR Increase to Improved Survival With Acoramidis - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

BridgeBio’s acoramidis shows promise in ATTR-CM study - Investing.com

May 19, 2025
pulisher
May 19, 2025

BridgeBio Pharma Reports Positive Phase 3 Results for Acoramidis, Highlighting Improved Survival Rates in ATTR-CM Patients - Nasdaq

May 19, 2025
pulisher
May 19, 2025

Breakthrough ATTR-CM Study: Higher TTR Levels from Acoramidis Directly Predict 31% Better Survival Rates - Stock Titan

May 19, 2025
pulisher
May 19, 2025

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study - Yahoo Finance

May 19, 2025
pulisher
May 15, 2025

Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday - MSN

May 15, 2025
pulisher
May 14, 2025

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade - MSN

May 14, 2025
pulisher
May 14, 2025

BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug - Yahoo

May 14, 2025
pulisher
May 14, 2025

Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Fibroblast Growth Factors (FGFs) Market reached US$ 303.75 - openPR.com

May 14, 2025
pulisher
May 13, 2025

Massive Sell-Offs Just Hit These 10 Stocks Today - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

BridgeBio (BBIO) Begins Dosing in ACT-EARLY Trial with Acoramidis | BBIO Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

BridgeBio launches landmark ATTR prevention study - Investing.com Australia

May 13, 2025
pulisher
May 13, 2025

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study - The Manila Times

May 13, 2025
pulisher
May 13, 2025

BridgeBio launches landmark ATTR prevention study By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 12, 2025

BridgeBio to Present Clinical Outcomes, Quality of Life Measures - GuruFocus

May 12, 2025
pulisher
May 12, 2025

BridgeBio Pharma to Present Key Findings on Acoramidis at Heart Failure Association Congress 2025 - Nasdaq

May 12, 2025
pulisher
May 12, 2025

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC - The Manila Times

May 12, 2025
pulisher
May 11, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

May 11, 2025
pulisher
May 10, 2025

(BBIO) Trading Report - news.stocktradersdaily.com

May 10, 2025
pulisher
May 10, 2025

Raymond James Financial Inc. Invests $456,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

May 10, 2025
pulisher
May 07, 2025

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 - The Manila Times

May 07, 2025
pulisher
May 06, 2025

Recursion cuts nearly half of its pipeline - statnews.com

May 06, 2025
pulisher
May 05, 2025

Achondroplasia Market: Epidemiology, Therapies, Companies, - openPR.com

May 05, 2025
pulisher
May 05, 2025

Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $53, Maintains Outperform Rating - marketscreener.com

May 05, 2025
pulisher
May 03, 2025

Mizuho Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail

May 03, 2025
pulisher
May 02, 2025

Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk - Benzinga

May 02, 2025
pulisher
May 02, 2025

BridgeBio (BBIO) Sees Surge in Bullish Option Activity | BBIO Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update - ADVFN

May 02, 2025
pulisher
May 02, 2025

BridgeBio (BBIO) Sees Surge in Bullish Option Activity | BBIO St - GuruFocus

May 02, 2025
pulisher
May 01, 2025

BridgeBio Pharma Stock (BBIO) Jumps on Strong Drug Launch - The Globe and Mail

May 01, 2025
pulisher
May 01, 2025

Cantor Fitzgerald Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail

May 01, 2025
pulisher
May 01, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q1 2025 Earnings Call Transcript - Insider Monkey

May 01, 2025
pulisher
May 01, 2025

High Growth Tech Stocks In The US Market May 2025 - simplywall.st

May 01, 2025
pulisher
May 01, 2025

BridgeBio Pharma First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 01, 2025
pulisher
Apr 30, 2025

Excellent Earnings Propelled Prices of These 10 Firms - Insider Monkey

Apr 30, 2025

Bridgebio Pharma Inc Azioni (BBIO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):